ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Dermata Therapeutics (DRMA)
Dermata Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$0.76▲ +5.15%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
41%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Dermata Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Dermata Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Dermata Therapeutics a 41% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $0.55 and $0.90; in 9 out of 10, between $0.36 and $1.37. Estimated annual volatility is 151%.
Price, last 12 months (weekly close)
Key numbers
- 52-week high
- $3.70
- 52-week low
- $0.60
- Revenue (12 months)
- $0.0M
- Return on equity
- -183.9%
- Free cash flow (12 months)
- $-5.1M
- Beta
- 0.69
What this means
ATLAS does not publish a fair value for DRMA right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks DRMA has traded between $0.60 and $3.70. Today it is 79.6% below that high and 27% above its low.
Its beta is 0.69: it tends to move less than the market.
About the company
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company focused on developing and commercializing products for medical and aesthetic skin conditions.
Want to see everything about Dermata Therapeutics?
Get started →Plans from €3.99 a month.
Frequently asked questions
What does Dermata Therapeutics do?
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company focused on developing and commercializing products for medical and aesthetic skin conditions.
What is the chance DRMA goes up next month?
41%: somewhat worse than a coin flip. In half of the simulated outcomes, DRMA ends the month between $0.55 and $0.90.
How volatile is DRMA?
ATLAS estimates annual volatility at 151%. In a typical month, half of the outcomes end between $0.55 and $0.90.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer